Product Details

Purity

Greater than 90% as determined by SDS-PAGE.

Target Names

TIGIT

Uniprot No.

Q495A1

Research Area

Immunology

Alternative Names

DKFZp667A205; ENSMUSG00000071552; FLJ39873; RGD1563191; T cell immunoreceptor with Ig and ITIM domains; TIGIT; TIGIT_HUMAN; V-set and immunoglobulin domain containing 9; V-set and immunoglobulin domain-containing protein 9; V-set and transmembrane domain containing 3; V-set and transmembrane domain-containing protein 3; VSIG9; VSTM3; Washington University cell adhesion molecule; WUCAM

Species

Homo sapiens (Human)

Source

E.coli

Expression Region

22-141aa

Target Protein Sequence

MMTGTIETTGNISAEKGGSIILQCHLSSTTAQVTQVNWEQQDQLLAICNADLGWHISPSFKDRVAPGPGLGLTLQSLTVNDTGEYFCIYHTYPDGTYTGRIFLEVLESSVAEHGARFQIP
Note: The complete sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application, please explicitly request the full and complete sequence of this protein before ordering.

Mol. Weight

26.0 kDa

Protein Length

Extracellular Domain

Tag Info

N-terminal 6xHis-SUMO-tagged

Form

Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Buffer

If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.

Troubleshooting and FAQs

Protein FAQs

Storage Condition

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.

Shelf Life

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.

Lead Time

3-7 business days

Notes

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Datasheet & COA

Please contact us to get it.

Description

The recombinant Human TIGIT protein is encoded by the gene of TIGIT (22-141aa). The gene of TIGIT was cloned in a system (E.coli) that supported the expression of TIGIT and translation of messenger RNA. Modification of TIGIT by recombinant DNA technology could lead to the expression of the target protein. The protein was fused with N-terminal 6xHis-SUMO tag in the production. The purity is 90% determined by SDS-PAGE.

TIGIT (VSIG9, VSTM3) is a protein coding gene that encodes T-cell immunoreceptor with Ig and ITIM domains. According to some studies, TIGIT may have the following features.
TIGIT, an inhibitory receptor expressed on lymphocytes, has recently been proposed as a major emerging target for cancer immunotherapy. TIGIT has an intrinsic suppressive function of T cells. The surface protein TIGIT inhibits T cell activation by promoting the generation of mature immunoregulatory dendritic cells. TIGIT is a key inhibitor of the cancer immune cycle. The immunosensor TIGIT regulates antitumor and antiviral CD8+ T cell effector functions. The TIGIT/CD226 axis regulates human T cell function. Interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. TIGIT, a new immunotherapy target, is moving from the lab to the bedside.

Target Background

Function

Binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells.

Gene References into Functions

The activation of PD-1 and TIGIT may exert negative regulatory effects and inhibit the immune response to cancer cells, resulting in immune escape of cancer cells. PMID: 30262800
These findings highlight the importance of the TIGIT/CD226/PVR axis as an immune checkpoint barrier that could hinder future "cure" strategies requiring potent HIV-specific CD8(+) T cells PMID: 28084312
High expression of TIGIT and Helios identifies CD4+ T cells with impaired immunological functions, primarily among patients with an advanced stage of Sezary syndrome. PMID: 27592800
Natural killer cells and cytotoxic T cells express both TIGIT and DNAM-1 receptors, and in certain cases their effector functions are dictated by TIGIT or DNAM-1 signaling. Agonist and antagonist antibodies targeting either TIGIT or DNAM-1 present many therapeutic options for diseases spanning from cancer to auto-immunity. (Review) PMID: 28035916
TIGIT contributes to functional T-cell impairment and associates with poor clinical outcome in acute myelogenous leukemia. The study suggests that blockade of TIGIT to restore T-cell function and antitumor immunity may represent a novel effective leukemia therapeutic. PMID: 26763253
Blimp-1 binds to the promoters of PD-1 and TIGIT and positively regulates their expression in patients with acute myeloid leukemia. PMID: 28629373
Data show that gastric cancer cells inhibit T-cell metabolism through CD155/TIGIT signaling. PMID: 28883004
Our data provide important structural and biochemical determinants responsible for the recognition of nectin-2 by TIGIT. PMID: 27978489
TIGIT is a powerful negative regulator of CD4(+) T cells in systemic lupus erythematosus. PMID: 28108989
TIGIT signaling in NK cells after MDSC coculture led to a decrease in the phosphorylation of ZAP70/Syk and ERK1/2. PMID: 27503932
energetic basis for the TIGIT/nectin-2 interaction and revealed that an "aromatic key" of nectin-2 is critical for this interaction, whereas variations in the lock were tolerated. PMID: 28515320
TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization. PMID: 26250578
implying that TIGIT exerts immunosuppressive effects by competing with DNAM-1 for the same ligand, CD155 PMID: 26842126
These findings identify TIGIT as a novel marker of dysfunctional HIV-specific T cells PMID: 26741490
This study shows that HBZ-induced TIGIT plays a pivotal role in attenuating host immune responses and shaping a microenvironment favorable to human T-cell leukemia virus type 1. PMID: 26735971
a novel mechanism that links TIGIT expression with NK-cell functional heterogeneity, and this mechanism might partially explain why individuals have different susceptibilities to infection, autoimmune disease, and cancer. PMID: 26171588
Human regulatory T cells expressing the receptors TIGIT and CD226 display widely divergent phenotypes in regard to expansion and activation. PMID: 25994968
TIGIT and PD-1 blockade additively increased proliferation, cytokine production, and degranulation of tumor-antigen-specific CD8 T cells and CD8 TILs. TIGIT and PD-1 regulate the expansion and function of these T cells in melanoma. PMID: 25866972
The results identify a bacterium-dependent, tumor-immune evasion mechanism in which tumors exploit the Fap2 protein of F. nucleatum to inhibit immune cell activity via TIGIT. PMID: 25680274
Findings suggest that TIGIT is a key checkpoint inhibitor of chronic antiviral and antitumor responses through impairing CD226 function when disrupting its homodimerization. PMID: 25465800
TIGIT/PVR ligation signaling mediates suppression of IFN-gamma production via the NF-kappaB pathway. PMID: 24817116
TIGIT is phosphorylated at its cytoplasmic tail after its ligation with PVR. PMID: 23154388
The Tim-3 pathway appears to control regulatory (Treg) and effector T cell balance via altering cell proliferation and apoptosis during hepatitis C virus infection. PMID: 22706088
TIGIT can inhibit T cell functions by competing with CD226 and can also directly inhibit T cells in a T cell-intrinsic manner. PMID: 22427644
data suggest a cis-trans receptor clustering mechanism for cell adhesion and signaling by the TIGIT/PVR complex and provide structural insights into how the PVR family of immunoregulators function PMID: 22421438
that soluble Vstm3 attenuates T-cell responses in vitro and in vivo PMID: 21416464
TIGIT exerts immunosuppressive effects by binding to poliovirus receptor and modulating cytokine production by dendritic cells. PMID: 19011627
a novel immunoreceptor, Washington University Cell Adhesion Molecule, which is expressed on human follicular B helper T cells, was described. PMID: 19197944
TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition. PMID: 19815499

Hide All

Subcellular Location

Cell membrane; Single-pass type I membrane protein.

Tissue Specificity

Expressed at low levels on peripheral memory and regulatory CD4+ T-cells and NK cells and is up-regulated following activation of these cells (at protein level).

Database Links

HGNC: 26838

OMIM: 612859

KEGG: hsa:201633

STRING: 9606.ENSP00000373167

UniGene: Hs.421750

Code	CSB-EP675446HU
Abbreviation	Recombinant Human TIGIT protein, partial
MSDS	MSDS Datasheet
Size	US$306
	Order now
Image	(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel. Based on the SEQUEST from database of E.coli host and target protein, the LC-MS/MS Analysis result of CSB-EP675446HU could indicate that this peptide derived from E.coli-expressed Homo sapiens (Human) TIGIT. Based on the SEQUEST from database of E.coli host and target protein, the LC-MS/MS Analysis result of CSB-EP675446HU could indicate that this peptide derived from E.coli-expressed Homo sapiens (Human) TIGIT.
Have Questions?	Leave a Message or Start an on-line Chat

Recombinant Human T-cell immunoreceptor with Ig and ITIM domains (TIGIT), partial

Product Details

Related Products

Customer Reviews and Q&A

Target Background

×CloseMessage